List of Excipients in Branded Drug MEPERIDINE HYDROCHLORIDE

Generic Drugs Containing MEPERIDINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	meperidine hydrochloride	0054-4595	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	meperidine hydrochloride	0054-4595	CROSCARMELLOSE SODIUM
Hikma Pharmaceuticals USA Inc	meperidine hydrochloride	0054-4595	LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	meperidine hydrochloride	0054-4595	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	meperidine hydrochloride	0054-4595	POVIDONE
Hikma Pharmaceuticals USA Inc	meperidine hydrochloride	0054-4595	STARCH, CORN
Teva Pharmaceuticals USA Inc	meperidine hydrochloride	0555-0381	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in MEPERIDINE HYDROCHLORIDE?

# Of NDCs	Excipient
2	ACETIC ACID
6	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM
2	HYPROMELLOSE 2910
3	LACTOSE MONOHYDRATE
2	MAGNESIUM STEARATE
1	POVIDONE

Meperidine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Meperidine hydrochloride is a mature, off-patent Schedule II opioid with limited growth potential as a conventional analgesic. The strongest commercial opportunities are in compliant injectable presentations, preservative-free hospital products, ready-to-administer formats, and supply-chain improvements. Excipient innovation has limited value unless it improves stability, compatibility, preparation time, or safety without increasing opioid exposure or introducing new regulatory risk.

What is the current commercial and regulatory position of meperidine hydrochloride?

Meperidine hydrochloride is approved in the United States for the treatment of moderate-to-severe pain and, in some labels, for preoperative medication and selected obstetric uses. It is available primarily as an injectable product and, depending on market and manufacturer, as oral tablets or oral solution.

Attribute	Meperidine hydrochloride
Active ingredient	Meperidine hydrochloride
Drug class	Opioid analgesic
U.S. controlled-substance schedule	Schedule II
Principal routes	Intramuscular, subcutaneous, intravenous; oral products in some markets
Common injectable strengths	25 mg/mL, 50 mg/mL, 100 mg/mL
Primary purchasers	Hospitals, emergency departments, procedural units, wholesalers
Patent position	Legacy molecule; original composition-of-matter protection expired
FDA pathway for new generic products	ANDA, subject to product-specific requirements
Biosimilar exposure	None
Main commercial constraint	Declining clinical use and opioid-safety concerns

FDA labeling warns about respiratory depression, seizures, serotonin syndrome, dependence, and accumulation of normeperidine, particularly with repeated dosing or impaired renal function (U.S. Food and Drug Administration [FDA], 2023a). The American Geriatrics Society lists meperidine as a medication to avoid in older adults because of limited effectiveness and a higher risk of neurotoxicity (American Geriatrics Society Beers Criteria Update Expert Panel, 2023).

Meperidine's clinical restrictions reduce the market available for premium excipient products. A formulation that raises manufacturing cost without improving hospital workflow or product safety is unlikely to obtain meaningful price support.

What excipients are used in meperidine hydrochloride injections?

The basic injectable formulation is relatively simple. U.S. labels for meperidine hydrochloride injection generally identify water for injection as the vehicle and hydrochloric acid and/or sodium hydroxide for pH adjustment. Exact excipient composition depends on the manufacturer, presentation, preservative status, and container system (DailyMed, 2024a).

Formulation element	Typical role	Commercial relevance
Water for injection	Aqueous vehicle	Standard parenteral solvent
Hydrochloric acid	pH adjustment	Supports solution stability and compatibility
Sodium hydroxide	pH adjustment	Controls final formulation pH
Benzyl alcohol, where used	Preservative in selected multidose products	Creates neonatal and preservative-sensitivity limitations
Nitrogen headspace, where used	Oxygen reduction	May limit oxidative degradation
Container closure system	Product protection and dose delivery	Important for adsorption, extractables, and breakage risk

The formulation strategy should begin with the intended presentation:

1. Single-dose ampoule or vial.
2. Preservative-free single-dose vial.
3. Multidose vial.
4. Ready-to-administer syringe.
5. Premixed infusion or dilute solution.
6. Oral solid or liquid dosage form.

The excipient package should not be copied across these formats without compatibility testing. Preservative requirements, container closure, allowable hold time, and extractables profiles differ substantially.

Which excipient strategy is strongest for injectable meperidine?

Preservative-free single-dose products

A preservative-free presentation is the most commercially defensible injectable opportunity. Hospitals increasingly favor products that reduce preservative exposure and preparation errors, especially when the product is supplied in a single-use format.

The product can use a minimal excipient system:

• Water for injection.
• Controlled pH adjustment.
• Low-particulate container closure.
• Low-sorption elastomer, if a vial is used.
• Compatible glass or polymeric syringe components.

The value proposition is operational rather than pharmacological. The manufacturer can target operating rooms, emergency departments, and hospital pharmacies seeking simplified administration and lower handling burden.

The label must clearly distinguish preservative-free and preserved products. A preserved multidose product may be unsuitable for neonatal use or specific patient groups. The product name, carton, vial label, and barcode should make the distinction visible.

Ready-to-administer syringes

A prefilled syringe can reduce dose preparation and shorten administration time. The principal technical risks are syringe compatibility, drug adsorption, stopper interaction, silicone oil, tungsten residues from glass manufacturing, and extractables from polymer components.

A ready-to-administer product may justify a premium if it provides:

• A validated labeled shelf life.
• A fixed concentration that reduces calculation errors.
• A tamper-evident unit-dose presentation.
• Barcoding compatible with hospital medication-administration systems.
• Clear differentiation from higher-strength products.

The commercial case is stronger for standardized emergency or procedural use than for broad outpatient demand. Meperidine remains a low-volume product relative to more commonly used opioids, so manufacturing scale and inventory turnover are critical.

Diluted and premixed infusion products

Premixed meperidine solutions could reduce manipulation in institutional settings, but the opportunity is narrower. The manufacturer would need to establish concentration, infusion compatibility, container stability, particulate control, and in-use conditions.

Potential presentations include:

• Low-concentration intravenous bags.
• Small-volume ready-to-use infusion containers.
• Standardized concentrations for procedural use.

The main barrier is demand. Hospitals may prefer alternative opioids with larger formularies and more established premixed products. A premixed meperidine product should be developed only where a defined institutional purchasing need exists.

What excipients are appropriate for oral meperidine hydrochloride products?

Oral meperidine has a smaller and more specialized opportunity than injectable meperidine. Conventional immediate-release tablets can use standard excipients such as microcrystalline cellulose, lactose or other diluents, starch, povidone, croscarmellose sodium, colloidal silicon dioxide, talc, and magnesium stearate. The selected composition must match the reference product's critical quality attributes for an ANDA.

For oral tablets, the most commercially relevant excipient objectives are:

• Robust content uniformity at low tablet strengths.
• Rapid and reproducible disintegration.
• Low friability.
• Consistent dissolution across manufacturing sites.
• Reduced sensitivity to humidity.
• Color and imprint differentiation between strengths.

Modified-release meperidine is a poor commercial target. It could increase opioid exposure duration and raise concerns regarding accumulation of normeperidine. A new extended-release formulation would likely require a 505(b)(2) strategy or full development program rather than a straightforward generic approach. The clinical and regulatory risk would be disproportionate to the expected market size.

Oral liquid formulations

An oral liquid could support patients unable to swallow tablets, but its excipient system introduces additional concerns:

• Preservative selection.
• Microbial control.
• Palatability.
• Alcohol content.
• Sugar content.
• Dosing-device accuracy.
• Pediatric safety.
• Accidental ingestion and diversion risk.

A sugar-free, alcohol-free liquid could have a niche value proposition, but the target population must be tightly defined. Meperidine is not generally preferred for pediatric or chronic use, limiting the commercial rationale for a new oral liquid.

What formulation patents protect meperidine hydrochloride?

Meperidine hydrochloride is an old small-molecule drug. Its original composition-of-matter patents and early formulation rights have expired. Current commercial value is therefore unlikely to come from broad active-ingredient patent protection.

IP category	Current relevance
Composition-of-matter patent	Expired
Basic tablet formulation	Generally unavailable as a durable barrier
Basic aqueous injection	Weak protection potential
Specific ready-to-administer device	Possible device or formulation rights
Novel stability package	Potentially protectable if technically non-obvious
New route or delivery system	Could support 505(b)(2) or other differentiated development
Method-of-use patent	Limited unless tied to a genuinely new indication
Manufacturing process patent	Possible, but difficult to enforce against ordinary generic production
Trade secret	Relevant for process controls, component selection, and analytical methods

A new patent strategy would need to claim a specific technical advantage, such as:

• Improved long-term stability in a defined container system.
• Reduced adsorption or precipitation.
• A novel preservative-free multidose system.
• A validated ready-to-administer device.
• A new combination with a non-opioid analgesic.
• A clinically differentiated delivery system.

A patent that merely claims routine pH adjustment or standard pharmaceutical excipients would face substantial validity and obviousness risk.

What is the Orange Book status of meperidine hydrochloride?

The FDA Orange Book identifies approved drug products and relevant patent and exclusivity information. For a legacy generic product such as meperidine hydrochloride injection, the principal regulatory pathway is generally an ANDA referencing an approved product. No biosimilar pathway applies because meperidine hydrochloride is a chemically synthesized small molecule, not a biologic (FDA, 2024a).

The practical exclusivity position is as follows:

Exclusivity issue	Assessment
New chemical entity exclusivity	Expired
Orphan exclusivity	Not a central protection mechanism
Pediatric exclusivity	No current commercial significance identified
Reference-product patent barrier	Legacy patents expired
Paragraph IV exposure	Possible for any newly listed patent, but no material modern barrier is apparent
Biosimilar competition	Not applicable
Generic competition	Established and structurally available

Because product listings and patent records can change, commercial diligence should rely on the current FDA Orange Book and Drugs@FDA records before filing or acquisition decisions (FDA, 2024a; FDA, 2024b).

When does meperidine hydrochloride lose exclusivity?

Meperidine hydrochloride lost core exclusivity decades ago. The commercial question is not when the active ingredient loses exclusivity, but whether a new presentation can obtain limited protection through formulation, device, manufacturing, or use claims.

Potential exclusivity mechanisms include:

• A 505(b)(2) product with a new route, dosage form, or delivery system.
• A patent covering a specific device or container system.
• Three-year exclusivity for certain new clinical investigations supporting a change or modification, where statutory requirements are met.
• Orphan-drug exclusivity only if an approved product qualifies for an orphan indication.
• Contractual exclusivity through hospital or wholesaler supply agreements.

These mechanisms would protect a defined product, not the meperidine molecule generally.

Are there Paragraph IV challenges or litigation affecting meperidine?

Meperidine has been available as a generic drug for many years. No major current Paragraph IV dispute or active patent litigation appears to define the U.S. market for standard meperidine hydrochloride injection or tablets in the public FDA records cited here.

The litigation risk is more likely to arise from a new differentiated product. Relevant disputes could involve:

• A ready-to-administer syringe patent.
• A novel preservative-free multidose system.
• A device or autoinjector.
• A 505(b)(2) delivery technology.
• Trade dress or product-name confusion.
• ANDA paragraph certifications against a newly listed patent.

A company seeking to launch a conventional meperidine generic should focus on product-specific FDA requirements, manufacturing reliability, and distribution economics rather than expect patent settlement value.

Which companies are challenging or competing with meperidine hydrochloride?

Competition comes from two directions: other meperidine suppliers and therapeutic substitutes.

Direct generic competition

Generic manufacturers and contract manufacturers may compete on:

• Injectable strength availability.
• Preservative-free status.
• Vial and ampoule formats.
• Supply continuity.
• Wholesaler contracts.
• Backorder performance.
• Unit price.

The market is vulnerable to shortages because demand is modest and multiple suppliers may not maintain large inventories. A reliable supplier can obtain institutional business even without meaningful patent exclusivity.

Therapeutic alternatives

Hospitals commonly compare meperidine with morphine, hydromorphone, fentanyl, oxycodone, ketorolac, and non-opioid multimodal analgesics. The alternatives often have stronger clinical adoption, broader protocol integration, or better suitability for repeated dosing.

Meperidine's principal remaining niches may include selected postoperative shivering protocols, short-term procedural use, or institutional situations where prescribers retain familiarity with the product. Even these uses face substitution pressure.

What manufacturing and IP barriers affect meperidine excipient products?

The main barriers are technical and operational rather than patent-based.

Sterile manufacturing

Injectable products require validated aseptic processing or terminal sterilization where feasible, container-closure integrity testing, particulate control, endotoxin testing, and compliance with applicable FDA current good manufacturing practice requirements.

Container compatibility

The sponsor should evaluate:

• Glass type and surface treatment.
• Elastomer composition.
• Syringe barrel and plunger materials.
• Silicone oil levels.
• Adsorption to polymer surfaces.
• Extractables and leachables.
• Light exposure.
• Oxygen exposure.
• Freeze-thaw stress.
• Shipping vibration.

Stability program

A stability strategy should include:

• Long-term and accelerated stability.
• Photostability.
• In-use stability after puncture or opening.
• Dilution compatibility.
• Hold-time studies.
• Particulate and subvisible-particle analysis.
• Assay and degradation-product methods.
• Container-closure integrity.

Regulatory chemistry

The excipient package must be justified in the product's chemistry, manufacturing, and controls section. A novel excipient or an unusual concentration can increase FDA questions, toxicology requirements, and development time. The lowest-risk approach uses established parenteral-grade excipients with precedents in the relevant route and concentration.

How strong is the patent estate for meperidine hydrochloride?

The patent estate is weak for the conventional drug product and potentially moderate for a narrowly defined delivery system.

Product concept	Patent strength	Commercial outlook
Conventional injection in vial	Low	Commodity hospital product
Preservative-free injection	Low to moderate	Useful differentiation, limited exclusivity
Prefilled syringe	Moderate if device claims are strong	Best practical premium opportunity
Premixed infusion	Moderate if stability and container claims are novel	Narrow institutional market
Immediate-release tablet	Low	Generic price competition
Oral solution	Low to moderate	Niche demand, higher formulation burden
Extended-release product	Potentially higher	High clinical and regulatory risk
Novel combination product	Potentially high	Requires clinical differentiation

Patent strength should be measured claim by claim. A narrow formulation patent may deter direct copying but will not prevent competition through a different excipient system or container. Trade secrets and supply agreements may provide more practical protection than patents for a mature injectable product.

What commercial opportunities exist for meperidine excipients?

The highest-probability opportunities are:

1. Preservative-free single-dose injection with reliable hospital supply.
2. Ready-to-administer syringe with standardized labeling and barcode compatibility.
3. Low-sorption container closure for improved dose accuracy.
4. Packaging that separates 25, 50, and 100 mg/mL strengths clearly.
5. Contract manufacturing for small hospital or regional markets.
6. A sugar-free, alcohol-free oral liquid where a defined institutional need exists.
7. Excipient and container platforms that can be reused across other injectable opioids.

The weakest opportunities are extended-release meperidine, pediatric positioning, and premium oral reformulations without a clear clinical or operational benefit. Meperidine's safety profile limits the ability to charge for convenience alone.

Key Takeaways

• Meperidine hydrochloride is an old, off-patent Schedule II opioid with established generic competition.
• The conventional injectable formulation has a simple excipient system centered on water for injection and pH adjustment.
• Preservative-free single-dose products and ready-to-administer syringes offer the strongest practical commercial opportunities.
• Excipient selection should prioritize stability, compatibility, particulate control, and hospital workflow.
• A standard formulation is unlikely to support durable patent exclusivity.
• Novel delivery systems may support a 505(b)(2) strategy, but clinical and regulatory risk is high.
• Biosimilar competition does not apply.
• The principal market risks are declining use, therapeutic substitution, opioid-safety restrictions, and limited volume.
• Manufacturing reliability and supply continuity are more important than broad patent protection for conventional products.

FAQs

Can benzyl alcohol be used in meperidine hydrochloride injection?

It can be used in selected multidose presentations where the formulation and labeling support preservative use. It creates additional safety, labeling, and patient-population constraints. A preservative-free single-dose product has a broader institutional value proposition.

Is a new meperidine hydrochloride tablet eligible for generic approval?

A conventional tablet may be eligible for an ANDA if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling. A materially different release profile or delivery system may require a 505(b)(2) application.

Does meperidine hydrochloride have biosimilar risk?

No. Meperidine hydrochloride is a chemically synthesized small molecule. Competition occurs through generic-drug pathways, not biosimilar applications.

Can excipients extend meperidine hydrochloride patent life?

Excipients alone do not extend protection for the active ingredient. A specific, non-obvious formulation or delivery system may support a new patent, but the claim would protect only the defined product configuration.

Which meperidine presentation has the best commercial potential?

A preservative-free, ready-to-administer injectable syringe has the strongest commercial rationale because it can reduce preparation steps and medication-handling risk. Its success depends on demonstrated hospital demand, component compatibility, and dependable supply.

References

American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081.

DailyMed. (2024a). Meperidine hydrochloride injection, USP: Prescribing information. U.S. National Library of Medicine.

U.S. Food and Drug Administration. (2023a). Meperidine hydrochloride injection: Full prescribing information. FDA.

U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. FDA.